{
    "nctId": "NCT03900637",
    "briefTitle": "PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate",
    "officialTitle": "Multi-institutional Study to Increase Breast Conserving Surgery (BCS) Rate With Personalized Neoadjuvant Strategy in ER Positive and HER2 Negative Breast Cancer Patients for Whom BCS is Not Feasible",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 122,
    "primaryOutcomeMeasure": "Conversion Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histopathologically and immunohistochemically confirmed ER+ and HER2- BC patients\n2. Stage I-IIIA BC patients with detectable tumor sizes\n3. BC patients for whom BCS is not feasible due to tumor sizes or locations (two surgeons at each institution evaluate the infeasibility of BCS)\n4. Patients without distant metastasis which were identified pathologically or radiologically\n5. Female patients \u2265 19 years\n\n   * Diagnosis of menopause is defined as no menstruation for 1-year or both ovaries removed surgically\n6. ECOG 0-2\n7. Patients with adequate bone marrow function\n\n   * Hemoglobin 10 g/dL, ANC 1,500/mm3, Plt 100,000/mm3\n8. Patients with adequate kidney function\n\n   * serum Cr \u2264 1.5 mg/dL\n9. Patients with adequate liver function\n\n   * Bilirubin: \u2264 1.5 times of upper normal limit\n   * AST/ALT: \u2264 1.5 times of upper normal limit\n   * Alkaline phosphatase: \u2264 1.5 times of upper normal limit\n10. Patients who decided to voluntarily participate in this trial with written informed consent\n\nExclusion Criteria:\n\n1. History of treatment for ipsilateral BC or breast carcinoma in situ\n2. Confirmed distant metastasis of BC\n3. History of cancer other than BC\n4. Pregnant (positive pregnancy test within a week of enrollment) or breast-feeding patients\n5. Uncontrolled severe infection\n6. Psychiatric illness or epilepsy\n7. Male BC patients\n8. Inability to understand and willingness to sign a written informed consent\n9. Mammographic extensive microcalcification\n10. Multicentral, Bilateral BC\n11. History of chemotherapy or endocrine therapy on contralateral BC for the past 2 years\n12. ER-\n13. HER2+\n14. Undetectable and unmeasurable primary tumor size",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}